Cárdenas-Araujo D, Gutiérrez-Aguirre CH

Language: Spanish
References: 31
Page: 41-49
PDF size: 288.12 Kb.

ABSTRACT

In the past years, remarkable advances have been achieved in the treatment of acute lymphoblastic leukemia in children and young adults. Over the last decade application of minimal residual disease in acute lymphoblastic leukemia has expanded significantly from a limited number of study groups in Europe and the United States to worldwide application. Minimal residual disease is highly predictive of relapse in children, adolescents, and young adults treated for acute lymphoblastic leukemia. Several techniques have been developed to complement and refine morphology in assessing response to treatment, including immunologic or molecular markers, fluorescent in situ hybridization, etc. This technologic advancement led to introducing the concept or minimal residual disease, which has challenged the conventional definition of “remission”.

REFERENCES

1. Pui CH, Boyett JM, Rivera GK, et al. Long-term results or total therapy studies 11,12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children’s Research Hospital. Leukemia 2000;14:2286-2294.

2. Berry DA, Zhou S, Higley H, et al. Association of Minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncol 2017;3(7):e170580.

3. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood 2015;126(8):964-971.

4. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group Study. Blood 2008;111(12):5477-5485.

5. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120(26):5173- 5180.

6. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7-12.

7. Campana D. Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol 2008;143(4):481-489.

8. Campana D, Coustan-Smith E. The use of flow cytometry to detect minimal residual disease in acute leukemia. Eur J Histochem 1996;40Suppl 1:39-42.

9. Van der Velden V, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-1034.

10. Bradstock KF, Janossy G, Tidman N, et al. Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. Leuk Res 1981;5(4-5):301-309.

11. Ciudad J, San Miguel JF, López-Berges MC, et al. Prognostic value of inmunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16(12):3774-3781.

12. Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006;108(1):97-102.

13. Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23(5):1083-1098.

14. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38(4):139-152.

15. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002;99(7):2315-2323.

16. Schrappe M. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program 2012;2012:137- 142.

17. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 Study. Blood 2010;115(16):3206-3214.

18. Coustan-Smith E, Sancho J, Behm FG. Prognostic importance of measuring early clearance of leukemia cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100(1):52-58.

19. Van der Velden V, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002;16(8):1432-1436.

20. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354(2):166-178.

21. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008;22(4):771-782.

22. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360(26):2730-2741.

23. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia: 30 year’s experience at St Jude Children’s Research Hospital. N Engl J Med 1993;329(18):1289-1295.

24. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18(7):1508-1516.

25. Pieters R, De Groot-Kruseman H, Van Der Velden V, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol 2016;34(22):2591- 2601.

26. Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96(8):2691-2696.

27. Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998;92(11):4072-4079.

28. Krejci O, van der Velden VH, Bader P, et al. Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group. Bone Marrow Transplant 2003;32(8):849-851.

29. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2005;106(2):458-463.

30. Eckert C, Flohr T, Koehler R, et al. Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment. Leukemia 2011;25(8):1305-1313.

31. Szczepanski T, van der Velden VH, Waanders E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol 2011;29(12):1643-1649.